Wellington Partners leads series-C for Sensimed

The company's current shareholders, the Sandoz Family Foundation, ELM Development and a number of entrepreneurs, also participated in the round.

The company will use the funds to finalise the approval of its Sensimed Triggerfish product in the US and China, and to commercialise the product globally. The business will also conduct post-marketing application trials while funding ongoing operations.

Company
Sensimed is a Lausanne-based company that focuses on the design, development, and commercialisation of integrated micro-systems for medical devices. The company spun out of the Swiss Federal Institute of Technology (EPFL) in 2003.

Sensimed Triggerfish is a non-invasive soft contact lens-based solution that seeks to manage glaucomatous disease and offer personalised treatment. The product provides 24-hour intraocular pressure (IOP) profiles that are documented on a patient registry and analysed using learning algorithms.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• Switzerland
• Wellington Partners